The use of biologic therapies for the treatment of ocular inflammation
Abstract
Purpose of review: The paper summarizes the available studies on the use, efficacy, and safety of biologic agents in the treatment of ocular inflammation. Methods: Presentation of the use of biologic agents for the treatment of ocular inflammation, with special emphasis on our experience. Results: Biologic agents were used in 12 patients treated for noninfectious uveitis/scleritis in the last 5 years. Ocular inflammatory disease was part of systemic autoimmune disease in 11 patients, in one the systemic disease was not established. The efficacy of biologics was good in all patients, there were less relapses of ocular disease and visual acuity was stable. The reactivation of pulmonary tuberculosis and herpetic uveitis occurred in one patient each. Summary: Biologic therapies, especially anti- TNF-α factor agents in the last years and interferons show a high efficacy in controlling noninfectious uveitis and scleritis, resistant to standard immunosuppressants. So far, our experiences with the use of biologics in our patients are good, but high costs and limited long-term experience restrict their use.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.